Recent events
Recent events tied to this brand in public sources.
Back to profile12 entries
2022
Shareholder derivative suit against Biogen board
The Booth Family Trust filed a derivative complaint on behalf of Biogen against its board in the District of Massachusetts, alleging breaches of fiduciary duties, violations of federal securities laws and other misconduct that caused damage to Biogen.
2021
Biogen announces a price reduction for Aduhelm
Biogen announced that Aduhelm would cost USD 28,200 per person for a person of average weight starting the following month, half the previously stated annual cost of USD 56,000.
2021
Biogen and MIT announce climate, health and equity collaboration
Biogen and MIT announced a collaboration aimed at accelerating science and action on climate change to improve human health. The collaboration is supported by a three-year, $7 million commitment from Biogen and the Biogen Foundation.
2021
FDA approves updated Aduhelm prescribing information
The FDA approved updated prescribing information for Aduhelm, emphasizing that treatment should be initiated in patients with mild cognitive impairment or mild Alzheimer’s dementia, the population studied in clinical trials.
2021
FDA approves Biogen's Aduhelm
The FDA approved Biogen's aducanumab, marketed as Aduhelm, for Alzheimer's disease.
2021
FDA approves Biogen’s Aduhelm
The FDA approved Biogen’s Alzheimer’s treatment Aduhelm, using an accelerated approval pathway despite uncertainty about its effectiveness.
2021
Biogen and Ginkgo Bioworks announce manufacturing partnership
Biogen and Ginkgo Bioworks announced an agreement under which Biogen will access Ginkgo’s cell-programming platform and Ginkgo will use its bioengineering capabilities to improve production of engineered viruses used in gene therapies. Biogen is paying $5 million upfront, with Ginkgo eligible for milestone payments.
2021
Atalanta Therapeutics announces collaboration with Biogen
Atalanta Therapeutics announced a strategic collaboration with Biogen to develop RNAi therapeutics for multiple targets, including Huntington’s disease and additional CNS targets.
2020
Biogen raises full-year guidance
Biogen raised its full-year revenue guidance after reporting better-than-expected second-quarter sales. The company now expects full-year revenues to reach between $34 and $36 per share, up from its previous estimate of between $31.50 and $33.50.
2020
Biogen announces Michael McDonnell as EVP and CFO
Biogen announced Michael McDonnell’s appointment as Executive Vice President and Chief Financial Officer, effective August 15, 2020.
2020
Biogen announces partnership to build COVID-19 biobank
Biogen announced a partnership with the Broad Institute and Boston-area hospitals to build a COVID-19 biobank for research. Biogen said it would collect blood samples from recovered employees who volunteer and attempt to collect samples from their close contacts.
2020
Biogen and Sangamo announce global collaboration
Biogen announced a global collaboration with Sangamo Therapeutics to develop gene regulation therapies targeting Alzheimer’s, Parkinson’s and other neuromuscular and neurological diseases.